Rpmi 1640 glutamax

Manufactured by Thermo Fisher Scientific

Sourced in United States, Germany, United Kingdom, France, Australia, Italy

RPMI 1640 GlutaMAX is a cell culture medium formulated to support the growth and maintenance of a variety of cell lines. It provides a balanced salt solution with amino acids, vitamins, and other essential components required for cell cultivation.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

RPMI 1640 medium with GlutaMAX RPMI 1640 W/GLUTAMAX-I RPMI-1640-Medium-GlutaMAX Supplement-HEPES RPMI 1640 Glutamax-I medium RPMI-1640-GlutaMAX media RPMI 1640 – Glutamax – HEPES medium RPMI-1640- GlutaMAX-I without phenol red RPMI-1640 Glutamax cell culture medium RPMI 1640 w/Glutamax RPMI 1640 + Glutamax growth medium

336 protocols using rpmi 1640 glutamax

Jurkat T Cell and Primary CD4+ T Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

Jurkat T cells (94% homology with Jurkat clone E6.1 validated by the SSTR method on the DSMZ website) were cultured at 37°C with 5% CO₂ in RPMI1640 Glutamax (Gibco; 61870-010) supplemented with 10% fetal calf serum (FCS; Eurobio; CVFSVF00-01) and were passed every 2–3 d at ∼0.5 × 10⁶ cells/mL.
Peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated using a Ficoll density gradient. Buffy coats from healthy donors were obtained from Établissement Français du Sang in accordance with INSERM ethical guidelines. CD4⁺ T cells were purified using the total CD4⁺ negative isolation kit (Miltenyi Biotec; 130-096-533). Primary CD4⁺ T cells were activated in six-well plates coated with anti-CD3e (OKT3; 317326; BioLegend) in presence of soluble anti-CD28 (CD28.2; 302914; BioLegend) during 6 d before use and cultured in RPMI1640 Glutamax (Thermo Fisher Scientific; 61870-010) supplemented with 10% FCS (Eurobio, CVFSVF00-01), 10,000 U/mL penicillin-streptomycin (Gibco; 15140-122), 1 M Hepes (Gibco, 15630-056), 50 mM 2-Mercaptoethanol (Gibco; 31350-010) and 20 U/mL recombinant IL-2 (Immunotools; 11340025).

Paillon N., Ung T.P., Dogniaux S., Stringari C, & Hivroz C. (2023). Label-free single-cell live imaging reveals fast metabolic switch in T lymphocytes. Molecular Biology of the Cell, 35(1), ar11.

+ Open protocol

+ Expand

Generation and Differentiation of Macrophages and Dendritic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Monocytes were kept in RPMI 1640 GlutaMAX supplemented with 10% FBS and Penicillin-Streptomycin (100 IU/mL) containing M-CSF (100 ng/mL; Peprotech) for 7 days to differentiate them into monocyte-derived macrophages (MDMs), refreshing the cytokine every 2–3 days. After 6–7 days: For differentiation into M1 macrophages, cells were supplemented with lipopolysaccharide (LPS) (50 ng/mL; Sigma Aldrich) and INF-γ (20 ng/mL; Peprotech). For differentiation into M2 macrophages, cells were kept with IL-4 (20 ng/mL; Peprotech) for one additional day.
For differentiation into monocyte-derived dendritic cells (moDC), monocytes were cultivated with IL-4 (250 IU/mL; Peprotech) and GM-CSF (800 IU/mL; Peprotech) for 7 days, refreshing the cytokines every 2–3 days. After 6–7 days, for differentiation into mature moDCs, DCs were supplemented with IL-6 (2,000 IU/mL; Peprotech), IL-1β (400 IU/mL; Peprotech) and TNFα (2000 IU/mL; Peprotech).
For co-cultures with genetically modified CD4 T cells, autologous monocytes were kept in RPMI 1640 GlutaMAX supplemented with 10% FBS and Penicillin-Streptomycin (100 IU/mL) containing M-CSF (100 ng/mL; Peprotech) for 15 days to differentiate them into MDMs before adding IL-4 (20 ng/mL; Peprotech) for one additional day prior to starting co-culture.

Albanese M., Chen H.R., Gapp M., Muenchhoff M., Yang H.H., Peterhoff D., Hoffmann K., Xiao Q., Ruhle A., Ambiel I., Schneider S., Mejías-Pérez E., Stern M., Wratil P.R., Hofmann K., Amann L., Jocham L., Fuchs T., Ulivi A.F., Besson-Girard S., Weidlich S., Schneider J., Spinner C.D., Sutter K., Dittmer U., Humpe A., Baumeister P., Wieser A., Rothenfusser S., Bogner J., Roider J., Knolle P., Hengel H., Wagner R., Laketa V., Fackler O.T, & Keppler O.T. (2024). Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells. Cell Reports Medicine, 5(4), 101483.

+ Open protocol

+ Expand

Isolation and Differentiation of Human Monocyte-Derived Microglia

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood obtained from Innovative Research, the San Diego Blood Bank, or drawn from human subjects at the University of California San Diego Health Sciences by density gradient centrifugation over Ficoll-Paque Plus (Cytiva). Human monocyte-derived microglia (MMG) were differentiated from primary human monocytes as described elsewhere [38–41 (link)]. Briefly, 6×10⁶ PBMCs ml⁻¹ were incubated in MMG media [RPMI 1640 Glutamax supplemented with 100 µg streptomycin ml⁻¹, 100 U penicillin ml⁻¹ (all Gibco), 10 ng CSF1, CSF2, and β-NGF ml⁻¹, and 100 ng CCL2 and IL-34 ml⁻¹ (all Peprotech)] for 4 h, after which non-adherent cells were removed by aspiration. Adherent cells were then washed with Dulbecco’s PBS (Gibco) and further incubated in MMG media for 14 days at humidified 37 °C, 5 % CO₂ with media changes every 3 days, at which point cells were cultured in RPMI 1640 Glutamax supplemented with 100 µg streptomycin ml⁻¹ and 100 U penicillin ml⁻¹ .

Campbell G.R., Rawat P., Teodorof-Diedrich C, & Spector S.A. (2023). IRAK1 inhibition blocks the HIV-1 RNA mediated pro-inflammatory cytokine response from microglia. The Journal of General Virology, 104(5), 001858.

+ Open protocol

+ Expand

Culturing Human Carcinoid Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four human carcinoid cell lines, two intestinal (CNDT2 and HC45) and two of pulmonary origin (NCI-H720 and NCI-H727) were used for experiments.
CNDT2 is a human midgut carcinoid cell line kindly provided by Lee M. Ellis M.D. Anderson Center Texas USA [28 (link)] and grown in DMEM/F12 with 15 mM HEPES (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FBS (Th. Geyer GmbH, Stuttgart, Germany), penicillin 100 U/mL and streptomycin 100 µg/mL (Life Technologies), 5 mL Sodium Pyruvate 100 mM (Sigma-Aldrich, St. Louis, MO, USA), 5 mL MEM NEAA 100x (Life Technologies), 5 mL L-Glutamine 200 mM 100x (Life) and 10 ng/mL NGF (Life Technologies) and kept at 37 °C/5% CO₂. HC45 is a human ileal carcinoid cell line kindly provided by Ricardo V. Lloyd Mayo Clinic [29 (link)] and kept in RPMI 1640/Glutamax (GIBCO, Waltham, MA, USA) supplemented with 10% FBS, 1% P/S and 10 ng/mL Insulin (Invitrogen, Carlsbad, CA, USA) at 37 °C and 5% CO₂.
NCI-H720 is an atypical and NCI-H727 is a typical human pulmonary carcinoid cell line obtained from ATCC (Boras, Sweden). Both cell lines were cultured in RPMI 1640 Glutamax supplemented with 10% FBS, penicillin 100 U/mL and streptomycin 100 µg/mL, 1 mM Sodium Pyruvate (Life Technologies) at 37 °C and 5% CO₂.
For experiments involving seeding cells into new plates, cells were always allowed to adhere overnight.

Døssing K.B., Kjær C., Vikeså J., Binderup T., Knigge U., Culler M.D., Kjær A., Federspiel B, & Friis-Hansen L. (2018). Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells. Genes, 9(7), 337.

+ Open protocol

+ Expand

Cultivation of B16 and LLC Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The B16 mouse melanoma cell line was obtained from ATCC (Rockville, Maryland, USA). The cells were maintained in vitro in RPMI-1640 GlutaMAX and Opti MEM GlutaMAX (1:1) (both from Gibco, USA) supplemented with 100 mg/ml streptomycin (Polfa, Poland), 100 U/ml penicillin (Polfa, Poland), 4.5 g/l glucose (Sigma-Aldrich Chemie GmbH, Germany), 0.5% sodium pyruvate (Sigma-Aldrich Chemie GmbH, Germany or HyClone, USA).
The mouse Lewis Lung Carcinoma (LLC) cell line was obtained from ATCC (Rockville, Maryland, USA). The cells were maintained in vitro in RPMI-1640 GlutaMAX (Gibco, USA) supplemented with 100 mg/ml streptomycin (Polfa, Poland), 100 U/ml penicillin (Polfa, Poland), 4.5 g/l glucose (Sigma-Aldrich Chemie GmbH, Germany), 0.5% sodium pyruvate (Sigma-Aldrich Chemie GmbH, Germany or HyClone, USA).
Both of cell lines were cultivated in medium supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich Chemie GmbH, Germany), in standard conditions at 37°C in a humid atmosphere (5% CO₂).

Kicielińska J., Szczygieł A., Rossowska J., Anger N., Kempińska K., Świtalska M., Kaszowska M., Wietrzyk J., Boratyński J, & Pajtasz-Piasecka E. (2016). Oral Administration of Polymyxin B Modulates the Activity of Lipooligosaccharide E. coli B against Lung Metastases in Murine Tumor Models. PLoS ONE, 11(2), e0148156.

+ Open protocol

+ Expand

Jurkat and Primary T Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Jurkat cells were maintained in RPMI 1640 + GlutaMAX™ (Gibco) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) and 1% penicillin-streptomycin (PenStrep, Gibco) and cultured in incubator with 5% CO₂ at 37^oC. Jurkat cells used for this paper was between passage #3–20 to ensure valid comparisons due to possibility of cell senescence after repeated culture. Human primary T cells were obtained from Stanford Blood Bank from a healthy male donor aged 30–40 (Unit #: W070518103112). T cells were negatively isolated by removing platelets and red blood cells. The cells were maintained in RPMI 1640 + GlutaMAX™ (Gibco) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) and 1% penicillin-streptomycin (PenStrep, Gibco) and cultured in incubator with 5% CO₂ at 37^oC. To stimulate T cells, 30 International Unit (IU) of IL-2/mL (Life Technologies, Lot #: 1988864) of media was added. To activate T cells, Dynabeads coated with CD31/CD28 antibodies (Life Technologies, Lot #: 00665258) were added in a 1:1 ratio and removed prior to transfection.

Tay A, & Melosh N. (2021). Mechanical stimulation after centrifuge-free nano-electroporative transfection is efficient and maintains long-term T cell functionalities. Small (Weinheim an der Bergstrasse, Germany), 17(38), e2103198.

+ Open protocol

+ Expand

Cell Line Culturing and NK Cell Isolation

Check if the same lab product or an alternative is used in the 5 most similar protocols

MDA-MB231 (NCI-DTP Cat# MDA-MB-231, RRID:CVCL_0062), T47D (NCI-DTP Cat# T-47D, RRID:CVCL_0553), SKBR3 (ATCC Cat# HTB-30, RRID:CVCL_0033), and MCF7 (NCI-DTP Cat# MCF7, RRID:CVCL_0031) cell lines were grown in RPMI-1640/Glutamax™ (Gibco) supplemented with 10% FBS and 100 U/ml penicillin/streptomycin (Gibco). The NK92 (ATCC Cat# PTA-6670, RRID:CVCL_2142) cell line and NK cells isolated from healthy donors (NKd) by positive selection (CD56 Positive Selection Kit; Stem Cell) were cultured in RPMI 1640/GlutaMax™ (Gibco) supplemented with 10% FBS and 300 U/mL rhIL2. All cell lines were originally obtained from ATCC, tested for Mycoplasma infection by PCR (Venor GeM OneStep; Minerva Biolabs) every 3–6 months and used at low passage (<50).

Chollat-Namy M., Ben Safta-Saadoun T., Haferssas D., Meurice G., Chouaib S, & Thiery J. (2019). The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death & Disease, 10(10), 695.

+ Open protocol

+ Expand

Isolation and Activation of CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs were isolated as described before and erythrocytes were depleted. Next, CD4+ T cells were isolated with magnetic beads according to the manufacturer’s instructions (Miltenyi Biotec). CD4+ T cells were incubated in RPMI 1640 Glutamax (Gibco) supplemented with 100 µM β-mercaptoethanol (Life Technologies) for 60 min 37°C and then stained extracellularly for CD4. Afterwards, 1×10⁶ cells were taken up in 500 µL prewarmed RPMI 1640 Glutamax (Gibco), supplemented with 100 U/mL penicillin/streptavidin (Gibco) and 10% FCS (Sigma) and incubated either with or without 20 ng/mL IL-23, 20 µg/mL anti-IL6 (BD Biosciences) and 2 µg/mL anti-IL22 (R&D) for 5 min at 37°C. Stimulation was stopped and cells were fixed by addition of cold 4% paraformaldehyde in phosphate buffered saline (PBS) and incubated for 10 min at room temperature. After a single wash with PBS, cells were permeabilised in 70% ice-cold methanol in PBS for 30 min on ice. The cells were then stained intracellularly for 30 min at room temperature with an antibody specific for phosphorylated STAT3 (pSTAT3) (BD Biosciences no. 557815) and analysed by flow cytometry.

Schmitt H., Billmeier U., Dieterich W., Rath T., Sonnewald S., Reid S., Hirschmann S., Hildner K., Waldner M.J., Mudter J., Hartmann A., Grützmann R., Neufert C., Münster T., Neurath M.F, & Atreya R. (2018). Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut, 68(5), 814-828.

+ Open protocol

+ Expand

Orthotopic 4T1-luc2-tdTomato Tumor Inoculation

Check if the same lab product or an alternative is used in the 5 most similar protocols

4T1-luc2-tdTomato cells (Perkin Elmer) were expanded in RPMI 1640 + GlutaMAX (Thermo Fisher Scientific) with 10% FBS for 5 days at 37°C and 5% CO₂ prior to inoculation. Cells were removed from culture flasks by incubation with trypsin for 10 minutes at 37°C and resuspended in RPMI 1640. Cells were then pelleted by centrifugation at 300 × g and washed with DPBS, and resuspended at 1 × 10⁷ cells/mL of DPBS. Orthotopic tumor inoculations were performed by injection of 5 × 10⁵ tumor cells resuspended in 50 μL DPBS (Life Technologies) into the fourth right mammary fat pad of 8- to 10-week-old female BALB/c mice (Jackson Laboratory). The cell line was confirmed to be pathogen free and authenticated by short tandem repeat DNA analysis and compared to the ATCC STR profile database (DDC Medical).

Zhang Y., Hughes K.R., Raghani R.M., Ma J., Orbach S., Jeruss J.S, & Shea L.D. (2021). Cargo-free immunomodulatory nanoparticles combined with anti-PD-1 antibody for treating metastatic breast cancer. Biomaterials, 269, 120666.

+ Open protocol

+ Expand

In Vitro Fibrosarcoma and MLS Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

The fibrosarcoma cell line HT1080 (available at ATCC, Manassas, VA, USA) (17 (link)), either wild-type or stably transfected with either FUS-DDIT3 in the pEGFPN1 vector or the pEGFPN1 vector only (18 (link)), and the MLS cell lines 402-91 (19 (link)), 2645-94 (20 (link)), and 1765-92 (20 (link)) were all cultured in complete media, containing RPMI 1640 GlutaMAX supplemented with 5% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin (all Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Cell line identities were controlled by the cell line authentication test performed by Eurofins (Linköping, Sweden). For transfected cells, the media was additionally supplemented with 500 µg/ml geneticin (Gibco, Thermo Fisher Scientific). Cells were kept at 37°C and 5% CO₂ and passaged using 0.25% trypsin and 0.5 mM EDTA (Gibco, Thermo Fisher Scientific).
For drug treatments, cells were treated for 24 h with 2.5 µM ruxolitinib (Selleckchem, Munich, Germany). For drug titration experiments, 1:2 dilution series, ranging from 3 µM to 5.9 nM, were used.

Dolatabadi S., Jonasson E., Andersson L., Luna Santamaría M., Lindén M., Österlund T., Åman P, & Ståhlberg A. (2022). FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma. Frontiers in Oncology, 12, 816894.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!